Document Detail


Issues, goals, and guidelines in selecting first-line drug therapy for hypertension.
MedLine Citation:
PMID:  2490815     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Modern antihypertensive therapy is enriched by an explosion in drug development that makes available increasingly specific agents whose effects have advanced our understanding of pressor mechanisms. This and other research into hypertensive mechanisms has defined the clinical, pharmacological, and endocrinologic heterogeneity of human hypertension. The sum of these developments is a greatly enhanced ability to identify curable and definable causes of hypertension and to pathophysiologically stratify the remaining cases of essential hypertension. Modern treatment can be much more specific than before. When long-term drug therapy is indicated, the regimen is more likely to achieve a primary goal for each patient, that is, the fewest possible drugs in the smallest amount and in lowest frequency. Two clinically quantifiable mechanisms for long-term arteriolar vasoconstriction can be identified within the spectrum of human hypertension. The first, renin-mediated vasoconstriction, is directly related to the plasma renin level. The second, sodium-volume-related vasoconstriction, is marked by a reciprocally subnormal renin level and involves abnormal sodium retention and calcium transport. A baseline renin-sodium profile can identify the pressure of one of these two forms of vasoconstriction and therefore is the key for the diagnosis of the two curable disorders that fully express one of the two pressor mechanisms--renovascular hypertension and primary aldosteronism. Renovascular hypertension, more common than once thought, is often cured by angioplasty. It is important to diagnose these curable forms before beginning long-term drug therapy. The renin-sodium profile, used in conjunction with serum potassium and creatinine measurements, is valuable not only in screening patients for curable forms, but also for stratifying the remainder according to the pathophysiological vasoconstrictor mechanism that underlies the hypertension. Converting enzyme inhibitors or beta-blockers are, by themselves, often effective in correcting the hypertension of high- or medium-renin patients, whereas calcium antagonists, diuretic agents, or alpha-blockers alone are most effective against the low-renin form of vasoconstriction. In the large midzone of renin values, if monotherapy fails, a rational basis for combined antirenin-antisodium volume therapies can be developed.
Authors:
J H Laragh
Related Documents :
557305 - Plasma renin activity during controlled hemorrhage in the dog.
7480965 - Acute effects of alpha-1 adrenoceptor antagonist, doxazosin on circulating vasoactive h...
9566045 - Effects of cholecystokinin, caerulein and pentagastrin on arterial blood pressure and p...
21071835 - Reduction of blood pressure by soybean saponins, renin inhibitors from soybean, in spon...
557305 - Plasma renin activity during controlled hemorrhage in the dog.
7480965 - Acute effects of alpha-1 adrenoceptor antagonist, doxazosin on circulating vasoactive h...
Publication Detail:
Type:  Journal Article; Research Support, U.S. Gov't, P.H.S.; Review    
Journal Detail:
Title:  Hypertension     Volume:  13     ISSN:  0194-911X     ISO Abbreviation:  Hypertension     Publication Date:  1989 May 
Date Detail:
Created Date:  1991-08-26     Completed Date:  1991-08-26     Revised Date:  2007-11-14    
Medline Journal Info:
Nlm Unique ID:  7906255     Medline TA:  Hypertension     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  I103-12     Citation Subset:  IM    
Affiliation:
Cardiovascular Center, New York Hospital-Cornell Medical Center, New York 10021.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Antihypertensive Agents / therapeutic use*
Arterioles / drug effects
Biological Transport
Calcium / metabolism
Captopril / administration & dosage
Health Planning Guidelines
Humans
Hypertension / drug therapy*
Hypertension, Renovascular / diagnosis
Kidney / blood supply
Renin / blood,  pharmacology
Sodium / pharmacology
Vasoconstriction / drug effects
Grant Support
ID/Acronym/Agency:
HL-18323-SCR/HL/NHLBI NIH HHS
Chemical
Reg. No./Substance:
0/Antihypertensive Agents; 62571-86-2/Captopril; 7440-23-5/Sodium; 7440-70-2/Calcium; EC 3.4.23.15/Renin

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Determination of ranitidine in plasma by high-performance liquid chromatography.
Next Document:  Angiotensin converting enzyme inhibitors. Present and future.